Skin autofluorescence, a non-invasive biomarker for advanced
Accumulation of advanced glycation end-products (AGEs) in skeletal muscle has been implicated in development of sarcopenia.

This study aimed to obtain further insight in the pathophysiology of sarcopenia and studied its relationship with skin AGEs in the general population.

In a cross-sectional analysis, 2744 participants of Northern European background, mean age 74.1 years were included from the Rotterdam Study. Skin AGEs were measured using AGE readerTMas Skin autofluorescence (SAF), appendicular skeletal mass index (ASMI) using iDXA, hand grip strength (HGS) using a hydraulic hand dynamometer and in a subgroup gait speed (GS) measured on an electronic walkway (n=2,080).

They defined probable sarcopenia (low HGS) and confirmed sarcopenia (low HGS and low ASMI) based on European working group on Sarcopenia revised criteria (EWGSOP2) cut-offs. Multivariate linear and logistic regression were performed adjusting for age, sex, body fat percentage, height, renal function, diabetes and smoking status.

-- The prevalence of low ASMI was 7.7%, probable sarcopenia 24%, slow GS 3%, confirmed sarcopenia 3.5%.

-- SAF was inversely associated with ASMI, HGS and GS.

-- One unit increase in SAF was associated with higher odds of probable sarcopenia and confirmed sarcopenia.

Conclusively, higher skin AGEs are associated with higher sarcopenia prevalence. Authors call for future longitudinal studies to explore the role of SAF as a potential biomarker of sarcopenia.